ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

STXS Stereotaxis Inc

2.18
-0.01 (-0.46%)
10 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Stereotaxis Inc AMEX:STXS AMEX Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.01 -0.46% 2.18 2.21 2.18 2.19 209,769 21:15:09

Stereotaxis to Report Third Quarter 2023 Financial Results on November 9, 2023

17/10/2023 2:05pm

GlobeNewswire Inc.


Stereotaxis (AMEX:STXS)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Stereotaxis Charts.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, 2023 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments.

What:Stereotaxis third quarter 2023 financial results conference call
  
When:Thursday, November 9, 2023, at 10:00 a.m. EST (7:00 a.m. PST)
  
Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 3519052.
  
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
  
Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:                                        David L. FischelChairman and Chief Executive Officer

Kimberly PeeryChief Financial Officer

314-678-6100Investors@Stereotaxis.com 

1 Year Stereotaxis Chart

1 Year Stereotaxis Chart

1 Month Stereotaxis Chart

1 Month Stereotaxis Chart

Your Recent History

Delayed Upgrade Clock